Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Targets for Alzheimer’s Disease


Affiliations
1 Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India
     

   Subscribe/Renew Journal


AD is predominant of causing mortality across the world. Various type of hallmarks has been exploring in this disease, like aggregates of β-amyloid, hyperphosphorylated tau proteins, dyshomeostasis of biometals, oxidative stress, reduction in Ach, etc. There is no test to diagnose AD and it not simple. The majority of putative disease-modifying treatments in development for Alzheimer's disease directed against the amyloid-β (A β) peptide. AD allowed for the development of the first generation of therapies that are somewhat specific for this disorder. Acetylcholine esterase, β-secretase, tau protein and NMDA are the essential targets involves in the treatment of Alzheimer’s disease. AChE inhibitors and NMDA blockade have proven that higher efficacy levels in AD and many authors considering that as "symptomatic" treatments.

Keywords

Alzheimer’s Diseases, β-Amyloid, Acetylcholine, A Cholinesterase Inhibitor, NMDA.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Alzheimer’s A. 2015 Alzheimer's disease facts and figures. Alzheimer's and dementia: the journal of the Alzheimer's Association. 2015 Mar; 11(3):332.

  • Sanmugam K. Depression is a risk factor for Alzheimer disease-review. Research Journal of Pharmacy and Technology. 2015 Aug 1; 8(8):1056.

  • Derflinger S, Sorg C, Gaser C, Myers N, Arsic M, Kurz A, Zimmer C, Wohlschläger A, Mühlau M. Grey-matter atrophy in Alzheimer's disease is asymmetric but not lateralized. Journal of Alzheimer's Disease. 2011 Jan 1; 25(2):347-57.

  • Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Archives of neurology. 2011 Sep 1; 68(9):1124-30.

  • Corona C, Pensalfini A, Frazzini V, Sensi SL. New therapeutic targets in Alzheimer's disease: brain deregulation of calcium and zinc. Cell death and disease. 2011 Jun; 2(6):e176.

  • Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, Sánchez-Benavides G, Huesa G, Morán S, Dal-Ré R, Camí J. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2016 Jun 1; 2(2):82-92.

  • Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017 Sep 1; 3(3):367-84.

  • Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alzheimer's research & therapy. 2016 Dec; 8(1):39.

  • Culter NR, Sramek JJ. Review of the nest generation of Alzheimer's disease therapeutics: challenges for drug development [J]. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(1):27-57.

  • Coman H, Nemeş B. New therapeutic targets in Alzheimer's disease. International Journal of Gerontology. 2017 Mar 1; 11(1):2-6.

  • https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447

  • Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Frontiers in aging neuroscience. 2014 Jul 29; 6:171.

  • Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K, Gupta N, Nair P, Tripathi T, Kumar A. Current and novel therapeutic molecules and targets in Alzheimer's disease. Journal of the Formosan Medical Association. 2016 Jan 1; 115(1):3-10.

  • Stahl SM, Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press; 2013 Apr 11.

  • Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001 Oct 25; 32(2):177-80.

  • Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimer's and dementia. 2013 Mar 1; 9(2):208-45.

  • Orejarena-Ballestas MC, Quiñonez-Pérez AM, Marín-Gutiérrez A. Estimulación cognitiva para pacientes con trastorno neurocognitivo mayor por enfermedad de alzheimer: revisión sistemática. Búsqueda. 2017 Dec 15; 4(19):208-26.

  • Crouch PJ, Barnham KJ. Therapeutic redistribution of metal ions to treat Alzheimer’s disease. Accounts of chemical research. 2012 Jun 29; 45(9):1604-11.

  • Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine. 2016 Jun 1; 8(6):595-608.

  • Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. Safety and tolerability of BAN2401-a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer's research and therapy. 2016 Dec; 8(1):14.

  • Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert opinion on biological therapy. 2012 Aug 1; 12(8):1077-86.

  • Zhang HY, Yan H, Tang XC. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cellular and Molecular Neurobiology. 2008 Feb 1; 28(2):173-83.

  • Raghubabu K, Swarup LS, Ramu BK, Rupakumari G, Narayanarao M, Ramdas C. Development and Validated Visible Spectrophotometric Methods for the Assay of Donepezil hydrochloride in Pharmaceutical preparations. Research Journal of Pharmacy and Technology. 2012 Feb 1; 5(2):228.

  • Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology. 2006 Feb 1; 9(1):101-24.

  • Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Current neuropharmacology. 2013 May 1; 11(3):315-35.

  • Lalut J, Santoni G, Karila D, Lecoutey C, Davis A, Nachon F, Silman I, Sussman J, Weik M, Maurice T, Dallemagne P. Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase. European journal of medicinal chemistry. 2019 Jan 15; 162:234-48.

  • Sehgal SA, Hammad MA, Tahir RA, Akram HN, Ahmad F. Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. Current neuropharmacology. 2018 Jul 1; 16(6):649-63.

  • Lichtenthaler SF. Alpha‐secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential. Journal of neurochemistry. 2011 Jan; 116(1):10-21.

  • Vincent B, Checler F. α-Secretase in Alzheimer's disease and beyond: mechanistic, regulation and function in the shedding of membrane proteins. Current Alzheimer Research. 2012 Feb 1; 9(2):140-56.

  • Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, Tüscher O, Fellgiebel A. Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. Neurology. 2014 Nov 18; 83(21):1930-5.

  • Olariu A, Yamada K, Nabeshima T. Amyloid pathology and protein kinase C (PKC): possible therapeutics effects of PKC activators. Journal of pharmacological sciences. 2005; 97(1):1-5.

  • Mancini F, De Simone A, Andrisano V. Beta-secretase as a target for Alzheimer’s disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Analytical and bioanalytical chemistry. 2011 Jun 1; 400(7):1979-96.

  • Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochimica et Biophysica Acta (BBA)-General Subjects. 2008 May 1; 1780(5):819-25.

  • Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. The Lancet Neurology. 2014 Mar 1; 13(3):319-29.

  • Menting KW, Claassen JA. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease. Frontiers in aging neuroscience. 2014 Jul 21; 6:165.

  • Pai V, Chandrashekar KS, Shreedhara CS, Pai A. In-Silico and In-Vitro correlation studies of natural β-secretase inhibitor: An approach towards Alzheimer's Disease. Research Journal of Pharmacy and Technology. 2017 Oct 1; 10(10):3506-10.

  • Ghosh AK, Brindisi M, Tang J. Developing β‐secretase inhibitors for treatment of Alzheimer’s disease. Journal of neurochemistry. 2012 Jan 1; 120:71-83.

  • Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine. 2003 Apr 3; 348(14):1333-41.

  • Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer’s disease. CNS drugs. 2003 Aug 1; 17(9):641-52.

  • Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological Reports. 2015 Apr 1; 67(2):195-203.

  • Shahnawaz Khan M, Amjad Kamal M, Tabrez S. Elucidating treatment of Alzheimer's Disease via different receptors. Current topics in medicinal chemistry. 2017 May 1; 17(12):1400-7.

  • Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. Journal of neural transmission. 2014 Aug 1; 121(8):799-817.

  • López LM, López EA, González CV, inventors; Universidade de Santiago de Compostela, assignee. Use of a spirolide, analogues and derivatives for treating and/or preventing pathological conditions linked to the tau and beta-amyloid proteins. United States patent application US 13/500, 018. 2012 Oct 11.

  • Reddy AR, Venkateswarulu TC, Indira M, Narayana AV, Lohita TN, Sriharsha M. Identification of Membrane Drug Targets by Subtractive Genomic Approach in Mycoplasma Pneumonia. Research Journal of Pharmacy and Technology. 2015 Sep 1; 8(9):1209.

  • Froestl W, Pfeifer A, Muhs A. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. Journal of Alzheimer's Disease. 2013 Jan 1; 34(1):1-14.

  • M. Vijey Aanandhi, Niventhi. A, Rujaswini. T, Hemalatha C.N, Praveen. D. A Comprehensive Review on the Role of Tau Proteins in Alzheimer’s Pathology. Research Journal of Pharmacy and Technology 2018; 11(2):788-790.

  • Martin-Rapun R, De Matteis L, Ambrosone A, Garcia-Embid S, Gutierrez L, M de la Fuente J. Targeted Nanoparticles for the Treatment of Alzheimer's Disease. Current pharmaceutical design. 2017 Apr 1; 23(13):1927-52.

  • Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in molecular medicine. 2009 Mar 1; 15(3):112-9.

  • Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, Matt L, Hell JW, Wisely EV, Oddo S, Xiang YK. β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer's disease models. Journal of Biological Chemistry. 2013 Feb 19:jbc-M112.

  • Pandey A, Pawar MS. Assessment of Nootropic Activity of Panchagavya Ghrita in Animal Models. International Journal of Scientific and Research Publications. 2015 Aug; 5(8):1-5.

  • Mishra P, Maurya RK, Dwivedi D. Effect of Dopamine on Alzheimer and Autism and Determination of Best Model Organism for Both.

  • Jindal V. Glaucoma A multifactorial disease and its multidimensional management. International Journal of Scientific and Research Publications. 2013; 3:1-3.

  • Pandey A, Pawar MS. Assessment of Nootropic Activity of Panchagavya Ghrita in Animal Models. International Journal of Scientific and Research Publications. 2015 Aug; 5(8):1-5.

  • Swathi GS. Death anxiety, death depression, geriatric depression and suicidal ideation among institutionalized and noninstitutionalized elders. International Journal of Scientific and Research Publications. 2014 Oct; 4(10):356-64.

  • Auti MS, Hulle NB. Advanced shoes with embedded position tracking and path guidance to keep track of Alzheimer’s patients. International Journal of Scientific and Research Publications. 2015; 5(1).

  • Ibrahim N, Aziz HA. Trends on natural organic matter in drinking water sources and its treatment. International Journal of Scientific Research in Environmental Sciences. 2014 Mar 1; 2(3):94.

  • Krishnapriya R, Padmaja M. Study on individual and combined toxicity of quinalphos and dimethoate on certain neurological aspects of giant fresh water prawn Macrobrachium rosenbergii (Deman, 1879). International Journal of Scientific and Research Publications. 2014; 4:1-5.

  • Sivapalan SR. Medicinal uses and pharmacological activities of Cyperus rotundus Linn-A Review. International Journal of Scientific and Research Publications. 2013 May; 3(5):1-8.

  • Reddy CB, Reddy GS, Reddy NA. Development and validation of UV spectrophotometric method for determination of trifluoperazine hydrochloride in bulk and pharmaceutical dosage form. International Journal of Scientific and Research Publications. 2012 Aug; 2(8):1-5.


Abstract Views: 237

PDF Views: 0




  • Targets for Alzheimer’s Disease

Abstract Views: 237  |  PDF Views: 0

Authors

S. Dhinakaran
Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India
T. Tamilanban
Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India
V. Chitra
Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India

Abstract


AD is predominant of causing mortality across the world. Various type of hallmarks has been exploring in this disease, like aggregates of β-amyloid, hyperphosphorylated tau proteins, dyshomeostasis of biometals, oxidative stress, reduction in Ach, etc. There is no test to diagnose AD and it not simple. The majority of putative disease-modifying treatments in development for Alzheimer's disease directed against the amyloid-β (A β) peptide. AD allowed for the development of the first generation of therapies that are somewhat specific for this disorder. Acetylcholine esterase, β-secretase, tau protein and NMDA are the essential targets involves in the treatment of Alzheimer’s disease. AChE inhibitors and NMDA blockade have proven that higher efficacy levels in AD and many authors considering that as "symptomatic" treatments.

Keywords


Alzheimer’s Diseases, β-Amyloid, Acetylcholine, A Cholinesterase Inhibitor, NMDA.

References